Candida biofilm formation on Provox®2 and Provox Acti Valve voice prosthesis;Tworzenie biofilmu Candida na protezach głosowych Provox® 2 oraz Provox Acti Valve

Otolaryngologia Polska

Volumn 64, Issue 6, 2010, Pages 358-364

  Nowak, Magdalena ^a   Kurnatowski, Piotr ^a  

^a NONE   (Poland)

Author keywords

Biofilm; Candida; SEM; Voice prosthesis

Indexed keywords

EID: 79551702053     PISSN: 00306657     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0030-6657(10)70587-4     Document Type: Article

References (26)

1. Bien S, Okła S. Analiza powikłañ zwia̧zanych z chirurgiczna̧ rehabilltacjá głosu i mowy u pacjentów po laryngektomil. Problemy zwiazane z wszczepieniem i wymiana̧ protez glosowych. Otolaryng Pol. 2006; 60: 129-34.
2. Op de Coul BM, Hilgers FJ, Balm AJ, van den Hoogen FJ, van Tinteren H. A decade of postlaryngectomy vocal rehabilitation in 318 patients. Arch Otolaryngol Head Neck Surg. 2000; 126: 1320-1328.
3. Van Weissenbruch R Bouckaert S, Remon JP, Nelis H, Aerts R, Albers FWJ. Chemoprophylaxis of fungal deterioration of the Provox silicone tracheoesophageal prosthesis in postlaryngectomy patients. Ann Otol Rhinol Laryngol. 1997; 106: 329-337.
4. Baillie GS, Douglas LJ. Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol. 1999; 310: 644-56.
5. Chandra J, Mukherjee PK, Leidich SD, Faddoul FF, Hoyer LL, Douglas LJ, i wsp. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res. 2001; 80: 903-908.
6. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother. 1995; 39: 2128-2131.
7. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents and Chemother. 2002; 46: 1773-1780.
8. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun. 2003; 71: 4333-4340.
9. Ramage G, Vandewalle K, Wickes BL, López-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents and Chemother. 2001; 45: 2475-2479.
10. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E i wsp. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med. 2002; 112: 380-385.
11. Celebi S, Hcimustafaoglu M, Ozdemir O, Ozkaya G. Nosocomial candidaemia in children: results of a 9-year study. Mycoses. 2008; 51: 248-257. (Pubitemid 351502573)
12. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg; 2008: 106, 523-529.
13. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999; 12: 80-96.
14. Verduyn Lunel FM, Meis JF, Voss A. Nosocomial fungal infections: candidemia. Diagn Microbiol Infect Dis. 1999; 34: 213-220.
15. Xess I, Jain N, Hasan F, Mandai P, Banerjee U. Epidemiology of candidemia in a tertiary care centre of north India: 5-year study. Infection. 2007: 35: 256-259.
16. Blankenship JR, Mitchell AP. How to build a biofilm: a fungal perspective. Curr Opin Microbiol. 2006; 9: 588-594.
17. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL. McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol. 2001; 183: 5385-5394.
18. Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun. 1994; 62: 915-921.
19. Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol. 2001; 18: 163-170.
20. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol. 2003; 11: 30-36.
21. Adam B, Baillie GS, Douglas LJ. Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J Med Microbiol. 2002; 51:344-349.
22. Al-Fattani MA, Douglas LJ. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J Med Microbiol. 2006; 55: 999-1008.
23. Hawser SP, Baillie GS, Douglas LJ. Production of extracellular matrix by Candida albicans biofilms. J Med Microbiol. 1998; 47: 253-256.
24. Henriques M, Azeredo J, Oliveira R. Candida albicans and Candida dubliniensis: comparison of biofilm formation in terms of biomass and activity. Br J Biomed Sci. 2006; 63: 5-11.
25. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapstiosis on bioprosthetic surfaces. Infect Immun. 2002; 70: 878-888.
26. Hilgers FJ, Ackerstaff AH, Balm AJ, van den Brekel MWM, Tan IB, Persson J. A new problem-solving indwelling voice prosthesis, eliminating the need for frequent Candida and .underpressure" - related replacements: Provox Acti Valve. Acta Otolaryngol. 2003; 123: 972-979.